Literature DB >> 30566903

Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study.

Martin Kužma1, Peter Vaňuga2, Ivana Ságová3, Dušan Pávai2, Peter Jackuliak1, Zdenko Killinger1, Neil C Binkley4, Renaud Winzenrieth5, Harry K Genant6, Juraj Payer1.   

Abstract

Introduction Impaired bone microarchitecture is involved in vertebral fracture (VF) development among acromegaly patients. Aim of the study Comparison of DXA-derived bone parameters, areal BMD (aBMD), trabecular bone score (TBS) and 3D-SHAPER parameters in acromegaly patients with healthy controls. Methods This cross-sectional study evaluated acromegaly patients and a control group of healthy subjects. In all subjects, a single measurement of pituitary axis hormone levels, bone turnover markers, aBMD, (total hip (TH) and lumbar spine (LS)), TBS and 3D-SHAPER of the proximal femur region was performed. All subjects underwent DXA assessment of VF using the semiquantitative approach. Results One hundred six patients with acromegaly (mean age 56.6 years, BMI 30.2 kg/m2) and 104 control subjects (mean age 54.06 years, 28.4 BMI kg/m2) were included. After adjustment for weight, LS aBMD, TBS and TH trabecular volumetric BMD (vBMD) remained lower (P = 0.0048, <0.0001 and <0.0001, respectively) while cortical thickness (Cth) at TH and neck remained thicker (P = 0.006) in acromegaly patients compared with controls. The best multivariate model (model 1) discriminating patients with and without acromegaly included TBS, TH trabecular vBMD and TH Cth parameters (all P < 0.05). Twenty-two VFs (13 acromegaly subjects) were recognized. In these subjects after adjustment for age, FN aBMD, TH cortical sBMD and TH cortical vBMD remained significantly associated with the prevalent VF (OR = 2.69 (1.07-6.78), 2.84 (1.24-6.51) and 2.38 (1.11-5.10) for neck aBMD, TH cortical sBMD and TH cortical vBMD respectively)). The AUCs were similar for each parameter in this model. Conclusions Acromegaly patients, regardless of VF presence, have lower trabecular bone quantitative parameters, but those with VFs had decreased cortical density.

Entities:  

Mesh:

Year:  2019        PMID: 30566903     DOI: 10.1530/EJE-18-0881

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  13 in total

1.  Direct effects of octreotide on osteoblast cell proliferation and function.

Authors:  E Vitali; E Palagano; M L Schiavone; G Mantovani; C Sobacchi; G Mazziotti; A Lania
Journal:  J Endocrinol Invest       Date:  2022-01-12       Impact factor: 4.256

2.  Prediction of Vertebral Fractures by Trabecular Bone Score in Patients With Ankylosing Spondylitis.

Authors:  Z Killinger; M Kužma; S Tomková; K Brázdilová; P Jackuliak; J Payer
Journal:  Physiol Res       Date:  2021-11-30       Impact factor: 1.881

3.  Fibroblast Growth Factor 23 and Klotho Are Associated With Trabecular Bone Score but Not Bone Mineral Density in the Early Stages of Chronic Kidney Disease: Results of the Cross-Sectional Study.

Authors:  Z Kužmová; M Kužma; A Gažová; M Kovářová; P Jackuliak; Z Killinger; J Kyselovič; J Payer
Journal:  Physiol Res       Date:  2021-11-30       Impact factor: 1.881

Review 4.  Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis.

Authors:  Gherardo Mazziotti; Andrea G Lania; Ernesto Canalis
Journal:  Nat Rev Endocrinol       Date:  2022-03-14       Impact factor: 43.330

Review 5.  Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis.

Authors:  Cláudia Ribeiro de Moura; Sara Campos Lopes; Ana Margarida Monteiro
Journal:  Pituitary       Date:  2022-07-22       Impact factor: 3.599

Review 6.  Update on vertebral fractures in pituitary diseases: from research to clinical practice.

Authors:  Flaminia Carrone; Salvatore Ariano; Sara Piccini; Davide Milani; Marco Mirani; Luca Balzarini; Andrea Gerardo Lania; Gherardo Mazziotti
Journal:  Hormones (Athens)       Date:  2021-02-19       Impact factor: 2.885

7.  Trabecular Bone Score and Osteoprotegerin as Useful Tools in the Assessment of Bone Deterioration in Acromegaly.

Authors:  Aleksandra Jawiarczyk-Przybyłowska; Jowita Halupczok-Żyła; Joanna Syrycka; Agnieszka Zembska; Justyna Kuliczkowska-Płaksej; Marek Bolanowski
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-21       Impact factor: 6.055

Review 8.  Insulin Resistance in Patients With Acromegaly.

Authors:  Greisa Vila; Jens Otto L Jørgensen; Anton Luger; Günter K Stalla
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-30       Impact factor: 5.555

9.  Association of Vitamin D Receptor Polymorphisms With Activity of Acromegaly, Vitamin D Status and Risk of Osteoporotic Fractures in Acromegaly Patients.

Authors:  Aleksandra Jawiarczyk-Przybyłowska; Jowita Halupczok-Żyła; Katarzyna Kolačkov; Łukasz Gojny; Agnieszka Zembska; Marek Bolanowski
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-24       Impact factor: 5.555

10.  Hip Structure Analyses in Acromegaly: Decrease of Cortical Bone Thickness After Treatment: A Longitudinal Cohort Study.

Authors:  Kristin Godang; Tove Lekva; Kjersti Ringvoll Normann; Nicoleta Cristina Olarescu; Kristin Astrid Berland Øystese; Anders Kolnes; Thor Ueland; Jens Bollerslev; Ansgar Heck
Journal:  JBMR Plus       Date:  2019-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.